NDAORALTABLET
Approved
Sep 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PERMITIL (fluphenazine hydrochloride) by Merck & Co. is clinical pharmacology fluphenazine hydrochloride has activity at all levels of the central nervous system as well as on multiple organ systems. Approved for the management of manifestations of psychotic disorders. First approved in 1959.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERMITIL (fluphenazine hydrochloride) is an oral antipsychotic tablet approved in 1959 for managing manifestations of psychotic disorders. The mechanism of action involves activity across multiple CNS levels and organ systems, though the precise therapeutic pathway remains unknown. It represents a first-generation typical antipsychotic with broad dopamine antagonism.
LOE Approaching
As LOE approaches, the PERMITIL brand team is likely consolidating resources and shifting focus toward generic manufacturing partnerships or managed care retention strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Fluphenazine hydrochloride has activity at all levels of the central nervous system as well as on multiple organ systems. The mechanism whereby its therapeutic action is exerted is unknown.
Indications (1)
Career Relevance
Working on PERMITIL offers limited career growth due to its LOE status and generic competition, but provides valuable experience in mature product management, payer negotiations, and institutional psychiatry market dynamics. Roles are primarily defensive and cost-focused rather than launch or innovation-driven.
Worked on PERMITIL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.